Inactive Instrument

Cubist Pharmaceuticals Inc Stock

Stocks

End-of-day quote Nasdaq
- ^USD	-

10/12/14	Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug	RE
09/12/14	Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback	RE

10/12/14	Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug	RE
09/12/14	Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback	RE
09/12/14	Merck : to take on superbugs with Cubist Pharma buy	RE
09/12/14	AstraZeneca : Merck to take on superbugs with Cubist Pharma buy	RE
09/12/14	Apple : S&P 500 posts worst day since Oct; energy shares sink	RE
08/12/14	Cubist Pharmaceuticals : options unusually active before Merck deal	RE
06/12/14	Cubist Pharmaceuticals : Merck in talks to acquire Cubist Pharmaceuticals for more than $7 billion - NYT	RE
21/05/13	Cubist Pharmaceuticals Inc : U.S. court ruling favors Cubist in patent case versus Hospira	RE

13/01/15	Cubist Pharmaceuticals : Announces Withdrawal of Listing of CVRs (CBSTZ) from NASDAQ Global Select Market	BU
20/12/14	Cubist Pharmaceuticals : Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections	BU
16/12/14	Cubist Pharmaceuticals : SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Cubist Pharmaceuticals, Inc. Regarding the Fairness of the Sale of the Company	PR
13/12/14	Cubist Pharmaceuticals : SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Cubist Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information	BU
12/12/14	Cubist Pharmaceuticals : CBST SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches Investigation of the Board of Directors of Cubist Pharmaceuticals, Inc. in Connection With the Fairness of the Sale of the Company to Merck & Co.	BU

21/12/14	Cubist Pharmaceuticals : meldet FDA-Zulassung seines neuen Antibiotikums ZERBAXA™ (Ceftolozan/Tazobactam) für komplizierte Harnwegsinfektionen und komplizierte intraabdominelle Infektionen
20/12/14	Cubist Pharmaceuticals : annonce l’approbation par la FDA du nouvel antibiotique ZERBAXA™ (ceftolozane/tazobactam) pour le traitement des infections urinaires compliquées et des infections intra-abdominales compliquées
09/12/14	Merck : compte toujours acheter Cubist malgré un souci sur le Cubicin
08/12/14	Cubist Pharmaceuticals : Merck & Co acquiert Cubist Pharma pour 8,4 milliards de dollars
08/12/14	Cubist Pharmaceuticals : Wall Street ouvre en baisse, l'Asie inquiète

Manager	Title	Age	Since
Karen Rogers PRN	Corporate Officer/Principal	-	-
Phyllis Rae Abbuhl SAM	Sales & Marketing	-	-
Frederick B. Oleson PRN	Corporate Officer/Principal	-	01/01/1997

Director	Title	Age	Since
Martin Hermanus Soeters BRD	Director/Board Member	72	01/09/2006
Kenneth J. Martin BRD	Director/Board Member	72	25/09/2013

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
REGENERON PHARMACEUTICALS, INC.	+1.18%	+4.47%	+43.64%	-0.22%	79.68B
SAMSUNG BIOLOGICS CO.,LTD.	-3.73%	+3.89%	-1.33%	+25.77%	50.61B
UCB	-1.08%	-2.49%	+15.29%	+167.10%	48.81B
CSL LIMITED	-0.66%	+3.90%	-48.98%	-47.71%	46.91B
BIOGEN INC.	+0.35%	+2.07%	+55.74%	-22.80%	30.86B
MODERNA, INC.	+0.41%	+18.95%	+138.26%	-35.93%	25.42B
INCYTE CORPORATION	-0.32%	+2.37%	+41.16%	+85.76%	24.48B
INNOVENT BIOLOGICS, INC.	-0.42%	+4.62%	+0.16%	+193.67%	21.2B
BRIDGEBIO PHARMA, INC.	-1.45%	+0.68%	+65.47%	+164.23%	16.39B
Average	-0.64%	+3.56%	+34.38%	+58.88%	38.26B
Weighted average by Cap.	-0.57%	+3.17%	+26.65%	+42.06%

Employees

Sector